Peptide Technology Platforms Power the Next Wave of Therapeutic Innovation

The pharmaceutical industry is witnessing an unprecedented surge in peptide-based therapeutics, driven by their unique ability to combine the target specificity of biologics with the manufacturing efficiency of small molecules. As GLP-1 agonists and other peptide drugs achieve blockbuster success,

2026-06-29

Peptide Drug Development Accelerates as Next-Generation Therapeutics Reshape the Pharmaceutical Landscape

The global pharmaceutical landscape is being reshaped by the rising prominence of peptide-based therapeutics, driven by their success in treating chronic diseases such as diabetes, obesity, and cancer. As more peptide candidates enter clinical pipelines and gain regulatory approval,

2026-06-22

Small Molecule CDMO Services Drive Agility and Innovation in a Complex Drug Development Landscape

The global pharmaceutical industry is undergoing a profound shift, yet small molecule active pharmaceutical ingredients (APIs) remain the backbone of modern therapeutics. As drug pipelines grow more complex and the demand for targeted therapies rises, the strategic role of small molecule CDMO services has never been more critical. From early development to commercial supply, these services are enabling faster timelines, regulatory success, and supply chain resilience.

2026-06-15

A Nucleophilic catalysis reaction: Phosphine-catalyzed strain-release alkynylation of bicyclo [1.1.0] butanes

2026-06-11

Peptide Ingredients for Enhancing Skin Volume

GLP-1 agonists, like semaglutide and tirzepatide, improve blood sugar control and promote significant weight loss by enhancing insulin secretion, reducing appetite, and slowing gastric emptying. They may also provide cardiovascular risk reduction benefits in people with type-2 diabetes.

2026-06-08

Sustained Release Formulation Gains Traction as Patient-Centric Therapies Drive Innovation

The pharmaceutical industry is increasingly embracing Sustained Release Formulation technologies as a means to improve patient adherence, reduce dosing frequency, and optimize therapeutic outcomes. From chronic disease management to targeted local therapies, sustained release systems are becoming a cornerstone of modern drug development.

2026-06-02

Peptide Drug Substance Manufacturing Powers Next-Generation Therapeutics

The global pharmaceutical landscape is being reshaped by the rising prominence of peptide drug substances, driven by the success of peptide-based therapies in treating chronic diseases such as diabetes, obesity, and cancer.

2026-05-26

Injectable Formulation Development Gains Momentum as Biologics and Complex Molecules Drive Demand

The pharmaceutical industry is witnessing a surge in demand for Injectable Formulation Development, fueled by the rapid expansion of biologics, peptide therapies, and complex small molecules. As more drug candidates require parenteral administration for optimal efficacy, the need for robust, scalable, and compliant injectable formulations has never been greater.

2026-05-19

JiuzhouPharma at API China 2026

2026-05-14

Small Molecule APIs Drive Next-Generation Pharmaceutical Innovation and Supply Chain Resilience

The global pharmaceutical industry is undergoing a profound shift, yet small molecule APIs remain the backbone of modern therapeutics. Despite the rise of biologics and advanced modalities,

2026-05-12

Topical Formulation Services Accelerate Innovation in Dermatology and Drug Delivery

The pharmaceutical sector is experiencing rapid growth in Topical Formulation Services, driven by increasing demand for targeted, non-invasive therapies. As dermatology pipelines expand and new delivery technologies emerge, Topical Formulation Services are becoming essential for translating complex molecules into safe, effective treatments for patients worldwide.

2026-04-30

Connecting Global Innovation Resources to Accelerate CDMO Capabilities | JiuzhouPharma Launches “Isolated Lab” in Japan

2026-04-24